Log in

Kymera Therapeutics Stock Forecast, Price & News

-3.50 (-9.19 %)
(As of 10/21/2020 12:00 AM ET)
Today's Range
Now: $34.57
50-Day Range N/A
52-Week Range
Now: $34.57
Volume112,487 shs
Average Volume182,578 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:KYMR



Sales & Book Value

Annual SalesN/A



Market Cap$1.49 billion
Next Earnings DateN/A
OptionableNot Optionable
-3.50 (-9.19 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KYMR News and Ratings via Email

Sign-up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kymera Therapeutics (NASDAQ:KYMR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Kymera Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Kymera Therapeutics

What price target have analysts set for KYMR?

5 brokers have issued 12-month price targets for Kymera Therapeutics' stock. Their forecasts range from $27.00 to $42.00. On average, they anticipate Kymera Therapeutics' share price to reach $34.75 in the next year. This suggests a possible upside of 0.5% from the stock's current price.
View analysts' price targets for Kymera Therapeutics

Who are some of Kymera Therapeutics' key competitors?

What other stocks do shareholders of Kymera Therapeutics own?

Who are Kymera Therapeutics' key executives?

Kymera Therapeutics' management team includes the following people:
  • Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 42, Pay $504.53k)
  • Mr. Bruce N. Jacobs CFA, Chief Financial Officer
  • Dr. Jared A. Gollob, Chief Medical Officer (Age 56, Pay $458.29k)
  • Dr. Bruce L. Booth Ph.D., D.Phil., Founder & Chairman (Age 46)
  • Dr. Richard Chesworth Ph.D., Chief Scientific Officer (Age 50)

When did Kymera Therapeutics IPO?

(KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

What is Kymera Therapeutics' stock symbol?

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

How do I buy shares of Kymera Therapeutics?

Shares of KYMR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kymera Therapeutics' stock price today?

One share of KYMR stock can currently be purchased for approximately $34.57.

How big of a company is Kymera Therapeutics?

Kymera Therapeutics has a market capitalization of $1.49 billion. Kymera Therapeutics employs 55 workers across the globe.

What is Kymera Therapeutics' official website?

The official website for Kymera Therapeutics is www.kymeratx.com.

How can I contact Kymera Therapeutics?

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The company can be reached via phone at 857-285-5300 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.